Nimrat Chatterjee

This study shows that targeting REV1 in colorectal cancer enhances chemotherapy sensitivity in a context-dependent manner and inhibits organoid growth.

This study shows that targeting REV7 with C10 sensitizes colorectal cancer cells to microtubule disruption, revealing a mitotic vulnerability.

This study shows that inhibiting REV1, a TLS polymerase, increases trinucleotide repeat instability in human cells, suggesting REV1 protects against TNR mutagenesis.

This study shows that RPS19 and RPL5 mutations in DBA impair DNA double-strand break repair, potentially explaining cancer risk in patients.

This study identifies impaired homologous recombination in SDS and DBA patient-derived cells, linking ribosomopathy genes to DNA repair defects and suggesting PARP inhibition as a potential therapeutic target.